Skip to content

ncRNAs in Exosomes of Cholangiocarcinoma

Exosomes-derived ncRNAs As Biomarkers In Cholangiocarcinoma Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03102268
Enrollment
80
Registered
2017-04-05
Start date
2017-05-01
Completion date
2020-03-31
Last updated
2017-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Biliary Stricture, Cholangiocarcinoma

Brief summary

Exosomes are part of extracellular vesicles(EVs), and can be secreted into the environment by many types of cells. It has been demonstrated that the content and function of exosomes depends on the originating cell and the conditions under which they are produced.Exosomes contain proteins,RNAs and lipid,which may transfer biological information and activities from donor cells to receptor cells. Non-coding RNAs are involved in many biological activities including tumor growth and metastasis. In this prospective translational study, preclinical and clinical phases have been designed. On the first step, the main goal is to characterize the ncRNAs of cholangiocarcinoma derived exosomes. This exosome biomarker may provide a useful diagnostic tool. As a second step, the study will evaluate the prognostic and predictive value of cholangiocarcinoma exosomes levels in plasma in a prospectively recruited cohort of cholangiocarcinoma patients before and after surgical resection.

Interventions

None listed

Sponsors

The Second Hospital of Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1.Provide signed informed consent. The subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign informed consent, approved by the Independent Ethic Committee (IEC)/Institutional Review Board (IRB) prior to the initiation of any study-specific procedures. 2.Men or women aged \>= 18 years. 3.Histology- or imaging-confirmed bile duct stricture. 4.Metastatic disease or locally advanced disease not amenable to curative surgery. 5.Radiographically assessable, non-measurable disease or measurable disease as per RECIST criteria. 6.Life expectancy of at least 8 weeks from the time of enrollment. 7.No other malignancy within the past 5 years. 8.No prior chemotherapy for advanced disease.

Exclusion criteria

\- 1.Pregnant or lactating females. 2.Significant neurological or psychiatric disorders (psychotic disorders, dementia or seizures) that would prohibit the understanding and giving of informed consent. 3.Active Hepatitis B or C or history of an HIV infection. 4.Active uncontrolled infection.

Design outcomes

Primary

MeasureTime frameDescription
Characterization of the ncRNAsUp to 3 years from start of studyCharacterization of the ncRNAs in tumor derived exosomes from cholangiocarcinoma patients before anti-cancer therapies and benign biliary stricture patients

Secondary

MeasureTime frameDescription
Overall survivalUp to 3 years from start of the studyCorrelation of exosomes-derived ncRNAs(at baseline and monthly during therapy until death) and time-to-event end-points
Progression-free survivalUp to 3 years from start of the studyCorrelation of exosomes-derived ncRNAs(at baseline and monthly during therapy until tumor progression) and time-to-event end-points

Countries

China

Contacts

Primary ContactLin Miao, MD
miaolinxh@163.com086-25-58509932

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026